OS after allogeneic HSCT. The effect of HSCT on OS was explored by excluding the effect of follow-up salvage therapy. (A) In patients in the TP53WT ITT population who advanced to HSCT, OS was numerically worse in the idasa-C group than in the placebo-C group, and those who did not receive HSCT had worse OS. (B) In patients in the TP53WT ITT population, excluding those who received follow-up salvage therapies, survival was similar between treatment groups in both those who received HSCT and those who did not.